Immune Parameters in The Prognosis and Therapy Monitoring of Cutaneous Melanoma Patients: Experience, Role, and Limitations
Figure 12
Peripheral blood immune populations evaluated in patients stage III before surgery/therapy (1) and 36 months followup in 6 visits (2–7). Percentage of circulating immune subpopulations (a) and CD4/CD8 ratio (b).
